TrialESC heart failure2025

The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure.

Anggoro Budi Hartopo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.